Atraumatically formed tissue composition, devices and methods of preparation and treatment

The device and method for atraumatic tissue processing address the challenges of harvesting large grafts by maintaining high cell viability and enabling uniform application of FTSGP and cartilage grafts in a sterile system, facilitating rapid and cost-effective wound treatment.

JP2024167232APending Publication Date: 2024-12-03TISSUEMILL TECHNOLOGIES LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024134137
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-26
Filing Date
2024-08-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for processing full-thickness skin grafts and cartilage transplants face challenges such as the inability to harvest large grafts without creating oversized auxiliary wounds, pain at the donor site, and the need for a closed sterile system that maintains high cell viability and uniform application over irregular wound surfaces.

Method used

A device and method for atraumatically processing tissue into particulate form in an aqueous suspension, using ultra-sharp blades and controlled agitation to maintain high cell viability, allowing for precise and uniform application of full-thickness skin graft particles (FTSGP) and cartilage grafts in a closed sterile system.

Benefits of technology

The process achieves high cell viability (>90%) and allows for rapid, sterile, and cost-effective treatment of wounds with FTSGP and cartilage grafts, suitable for large areas and irregular surfaces, with application methods including syringes, sprays, and pastes, completed within 10-30 minutes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167232000001_ABST
    Figure 2024167232000001_ABST
Patent Text Reader

Abstract

To provide a system for treating the skin or cartilage of a patient.SOLUTION: A system includes: a sterile vessel for forming small pieces of biological tissue in a liquid suspension; a fragmentation device supported within the vessel; an opening inside the vessel in fluid communication with a removable dispensing device; a separator for isolating the formed small pieces from the liquid, and the removable dispensing device for receiving the filtered small pieces, where the formed small pieces move through the opening of the vessel into the dispensing device.SELECTED DRAWING: Figure 15A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 843,724, filed May 6, 2019, U.S. Provisional Patent Application No. 62 / 844,232, filed May 7, 2019, and U.S. Provisional Patent Application No. 16 / 584,755, filed September 26, 2019, the contents of which are incorporated by reference in their entireties herein.

[0002] The present invention relates to a process, method, apparatus, and system for preparing finely morselized tissue particles (TP) in a liquid medium atraumatically. The term tissue particles (TP) is meant to include tissues harvested from full thickness skin grafts (FTSG), split skin grafts (SSG), cartilage grafts (CG), or other organ transplant tissues, which are then subjected to the process described herein to generate small morselized tissue particles that retain their viability during the morselization process. The resulting product of this process can be a suspension of TP in an aqueous suspension, including highly viable interconnected tissue cells and extracellular matrix material, such as full thickness skin graft or cartilage graft particles, which can be rapidly prepared in a closed sterile system at the bedside, as an office procedure, or in the operating room, and conveniently and uniformly delivered with a syringe or other controllable application method to treat wounds / injuries / defects in the body. TPs such as FTSG, CG suspensions can be used as appropriate in plastic surgery, orthopedics, or other surgical applications such as wound healing, cosmetic surgery, joint surgery, etc. The term morselized TP, for purposes described herein, is meant to refer to finely cut, highly viable tissue that has been processed in accordance with the present invention, including various sizes and shapes. In the case of skin, the morselized TP is desirably FTSG. [Background technology]

[0003] There are many challenges that must be overcome when processing tissue for graft applications. For the treatment of skin wounds, the most effective graft is a full-thickness skin graft. A full-thickness skin graft includes the entire epidermis and dermis, so most of the characteristics of the grafted skin can be maintained in the process. However, when grafting an FTSG, the entire dermal layer must be removed, so the resulting skin graft donor site does not support regeneration and must be sutured closed. Thus, only small FTSGs can be used with current methods. Nevertheless, the result of an FTSG is a graft that maintains more of the normal characteristics of skin (especially texture, color, and thickness) and is less likely to shrink as it heals. This makes the FTSG a more aesthetically pleasing option for grafts.

[0004] Alternatively, to treat larger wound areas, physicians use split-thickness skin grafts (STSGs). This is because the resulting donor site can heal naturally over time with appropriate wound dressing. STSGs contain only the epidermis and variable portions of the dermis, leaving enough dermis for the donor site to heal by re-epithelialization without the need to close the wounded donor site with sutures. However, these donor sites are painful, heal slowly, and the harvested STSG grafts are often not large enough to cover large wound areas. The STSGs are then meshed to allow smaller sections of tissue to be expanded to effectively cover larger areas. The combination of mesh appearance, variable pigmentation, and thinness makes STSGs less cosmetically appealing than FTSGs. Most STSG procedures must be performed in an operating room setting.

[0005] Various techniques and systems have been developed for different types of surgical applications to effectively treat large wounds, improve donor site healing, and allow procedures to be performed on an outpatient basis.

[0006] Some techniques focus on harvesting only the epidermis rather than including split or full thickness dermis. Using only the epidermis, the topmost outermost layer of skin, as a grafting technique has its uses, but is the most limited in its efficacy as it does not include the structural components or cells of the dermis that are desirable for improved healing.

[0007] One such commercially known device for harvesting epidermal tissue is the Cellutome epidermal harvesting system, sold by KCI, a company called Acelity. This system uses a vacuum to create a series of epidermal microdomes at a donor site. These domes are then cut by hand using a blade and transferred to the patient using an adhesive pad. This technique provides only 42 small epidermal skin patches, which can be performed outside of an operating room and are only suitable for grafting superficial wounds in small areas. Because these epidermal grafts do not contain the structural components or cells of the dermis, these grafts work best on superficial wounds and result in a small superficial donor site that requires healing, although faster than STSG donor sites.

[0008] A recent variation of the split thickness skin grafting technique is the Xpansion Micro Auto Grafting Kit, sold by Acell. The device consists of disposable instruments designed for use in harvesting, mechanical preparation, and application of split thickness skin autografts for the purpose of grafting into wounds. In a commercial setting, the technique involves manually harvesting small split thickness skin grafts using a hand dermatome type device, further chopping the grafts by hand using a series of parallel cutting disc blades, and then spreading the chopped pieces over a larger wound area using a spatula. This process still results in a donor site that requires healing and also presents challenges with the need to remove the chopped tissue from between stacked parallel roller blades, and the handling and transport or small pieces of the graft.

[0009] A recent variation of the full-thickness skin graft technique is described in US Patent Application Publication Nos. 2016 / 0310159 and 2016 / 0310157 as a harvesting device to process full-thickness skin grafts. The device utilizes a row or array of adjacent hollow needle-tip tubes and utilizes ultrasound to coring and capturing tubular micro-columns of full-thickness skin samples from a donor site. The tubular columns of tissue array are intended to be interspersed across the wound site (the graft site). This technique requires a large number of harvested tissue micro-columns, but the device is limited by the limited number of columns it can achieve with each use. Also, like the Cellutome or Xpansion devices, this device creates auxiliary donor sites that need to heal, and the resulting tissue morphology is difficult to spread evenly across an irregular wound site, making it unsuitable for grafting over large areas.

[0010] Heretofore, the means to effectively use some grafts for transplantation in surgical applications such as full thickness skin grafts, split thickness skin grafts, cartilage transplants, etc. have remained poorly resolved. Unresolved problems of how to best process tissues such as skin grafts or cartilage grafts in an effective manner with known prior art methods and devices include, among others: 1) the inability to harvest large full thickness skin grafts without creating too large auxiliary wounds, limiting the gold standard for skin grafting, FTSG, to very small grafts that can be closed with sutures; 2) the creation of painful and slow healing donor sites with STSG; 3) the inability to achieve transplant tissue morphology from skin grafts or cartilage grafts with high cell viability that are quick to process, easy to manipulate in a closed sterile system, and apply uniformly to wounds with irregular surfaces; and 4) the inability to process full thickness skin grafts in a time and cost effective manner that can be expanded to cover larger areas or processed to treat chronic or contaminated wounds. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] US Patent Application Publication No. 2016 / 0310159 [Patent Document 2] US Patent Application Publication No. 2016 / 0310157 Summary of the Invention

[0012] This disclosure addresses many of the aforementioned problems of biological tissue processing. The device and processing method are specifically designed to process tissue, which is harvested non-traumatically in particulate form in an aqueous suspension with very high cell viability that can be easily distributed into the wound. Using full thickness skin containing all skin cell types and dermal extracellular matrix, the graft can be harvested from the donor site, the donor site can be fully sutured closed during the procedure, and the tissue can then be processed to cover a much larger area than the original skin area with a graft containing highly viable autologous skin cells. The closed system device and aqueous environment allows for convenience, ease of transfer, and control of sterility, temperature, and pH without compromising the viability of the tissue cells of the skin or cartilage graft. The resulting graft form is in liquid or paste form and can be distributed precisely and uniformly as needed. In the case of cartilage or cartilage, the graft can be harvested from the non-articulating area, processed, and implanted into the cartilage defect.

[0013] In the example of full thickness skin, containing all tissue components of the skin, the abundance of resulting easily minced tissue morphologies, which are a mixture of viable dermal and subcutaneous cells and stromal tissue components, exceeds the capabilities of other currently available devices and practiced methods.

[0014] Thus, in one aspect of the present invention, a full thickness skin graft (FTSG) composition is provided that includes a plurality of mechanically separated full thickness skin graft particles (FTSGPs) present in a liquid medium. The composition includes an FTSGP that includes full thickness skin cells and extracellular matrix material. A majority of the plurality of skin cells within the FTSGP are desirably viable after treatment, and at least about 50% of the skin cells within the FTSGP are viable after treatment.

[0015] The FTSGP has an average size measured in the largest dimension of about 200μ to 1500μ (0.020mm to 1.50mm), preferably about 350μ to 1250μ (0.35mm to 1.25mm), more preferably about 500μ to about 1000μ, and even more preferably about 500 to about 750μ or 250μ to 750μ, as compared to the specific surgical implant application. The nominal average size of the tissue morsels can be controllably varied by the duration and / or speed of mechanical processing as desired for the specific surgical implantation purpose. The overall process can be completed appropriately to optimally maximize the cell viability of the tissue graft material from the time of harvesting to the time of autologous implantation. The morselization process can be effectively completed within, for example, 3 to 10 minutes, as compared to the type of tissue being processed and the nominal tissue particle size desired for the specific surgical application.

[0016] In the case of TP, or skin, the FTSGP may be formed by atraumatically slicing the FTSG into particles in a liquid medium using the device described further herein. Desirably, the liquid medium may be a hydrophilic medium, but may also be a lipophilic medium. The FTSGP may be suspended in the liquid medium. The liquid medium itself may be in the form of a solution, emulsion, suspension, and combinations thereof.

[0017] The present invention will treat tissue including all cell types and extracellular matrix components of the treated tissue. In the case of full thickness skin, this includes all epidermal and dermal cells, as well as skin adnexal cells and extracellular matrix.

[0018] In another aspect of the invention, a) a container for containing a fluid and for receiving the tissue; b) a pair of cutting devices supported in juxtaposition within the container, at least one of the cutting devices being movable relative to the other cutting device to slice tissue therebetween; and c) an agitation device that causes repeated flow of fluid and fluid-suspended tissue through the juxtaposed cutting devices, the agitation device moving in coordination with at least one movable cutting device to repeatedly move fluid and tissue through the juxtaposed cutting devices.

[0019] At least one of the movable cutting devices may be adjacent to the other cutting devices. The movable cutting device may be attached to the agitator device for movement or integrated therewith. One of the juxtaposed cutting devices may be fixed.

[0020] The agitator induces a circulatory flow of fluid and tissue through the apposed cutting blades. Desirably, the agitator creates a vortex propulsive motion of fluid and tissue through the space between the apposed cutting blades. The agitator can take a variety of forms, and desirably, the agitator includes or is an impeller for inducing a circulatory flow of fluid and tissue through the apposed cutting blades. Also, desirably, the agitator and movable blade are rotationally movable about an axis.

[0021] As can be seen from the figures and description, the impeller preferably has a curved surface along said axis to induce continuous circulatory movement of the fluid and tissue. Furthermore, at least one of said cutting devices includes radially arranged blades with angular spaces therebetween, and preferably the other cutting device includes a plurality of said blades radially arranged with curved angular spaces therebetween. The angular spacing between the blade edges of the movable cutting device may be different than the angular spacing of the blades of the juxtaposed cutting devices. The cutting devices may be in physical contact along a common shearing surface.

[0022] As described, the container includes an opening for receiving the fluid and tissue and may include an outlet for discharging the fluid and processed tissue. The system may also include a dispensing device in fluid communication with the outlet for receiving the discharged fluid and processed tissue. The dispenser may be selected from a variety of devices including a syringe, which is particularly useful as it is an accurate and easy way to dispense morselized tissue particles or particularly a fluid composition containing FTSGP to a wound area.

[0023] As noted above, the present disclosure further includes a method for forming the treated tissue into a particulate form, the method comprising: providing a container for supporting a pair of side-by-side cutting devices; placing a fluid and organ tissue in said container; moving at least one of the cutting devices to cut the organ tissue; and providing an agitation device for continuously moving fluid and tissue through the cutting device to repeatedly slice or cut the tissue into progressively smaller particles.

[0024] The method may further include providing a dispensing device in fluid communication with the outlet and expelling the fluid and tissue into the dispensing device.

[0025] In another embodiment of the present disclosure, a plurality of full thickness skin graft particles (FTSGP) are included, desirably comprising: providing a container for supporting a pair of side-by-side cutting devices; placing the fluid and tissue in a container; moving at least one cutting device to cut the tissue or, in some cases, the FTSG tissue; and providing an agitation device for continuously moving the fluid and the organ tissue through a cutting device to repeatedly cut the tissue into progressively smaller particles.

[0026] As previously mentioned, in such products containing a plurality of tissue particles (TPs) or in one case full thickness skin graft particles (FTSGPs), the particles are desirably processed and distributed in an aqueous suspension, and a majority of the plurality of FTSGPs are viable after processing, desirably at least 50% or more. This high viability is due to a number of factors, including the use of atraumatic slicing with the device of the present invention, the use of a liquid biologically friendly medium, such as saline or other isotonic compatible medium that can buffer the Ph and prevent drying. As previously mentioned, the choice of liquid medium can be either hydrophilic, lipophilic, or can have aspects of both, such as an emulsion. The process can also be temperature controlled so that excessive heat is not generated and the cells are not adversely affected. Although various sizes of morsels are contemplated, in some embodiments, the TPs or FTSGPs have an average size measured across their largest dimension of about 150μ to about 1000μ.

[0027] Smaller particle size allows for easier dispensing through devices such as syringes that are familiar to practitioners and can be easily manipulated to control deposition at the wound site. For example, particles less than 400μ nominal are useful for delivery through an 18 gauge needle, and particles less than 200μ nominal are useful for delivery through a 22 gauge needle.

[0028] For subcutaneous implantation by needle injection, the epidermis is removed prior to injection. This can be done in several ways and is a routine surgical procedure. Once the epidermis is removed, only the dermal elements are processed and only the dermal elements without the epidermis can be injected into the dermis or subdermal plane. This overall process is otherwise the same as for processing other tissues or full thickness skin. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 is a cross-sectional view showing a processing apparatus for morselizing a tissue graft full thickness skin graft (FTSG). [Diagram 2] FIG. 1 is a cross-sectional view showing a processing apparatus for morselizing a tissue graft full thickness skin graft (FTSG). [Diagram 3] FIG. 1 is a cross-sectional view showing a processing apparatus for morselizing a tissue graft full thickness skin graft (FTSG). [Figure 4] FIG. 1 is a cross-sectional view showing a processing apparatus for morselizing a tissue graft full thickness skin graft (FTSG). [Diagram 5] FIG. 5 is a diagram showing a detailed schematic diagram of a fragmentation mechanism of the processing apparatus of FIGS. 1 to 4. [Figure 6] FIG. 5 is a diagram showing a detailed schematic diagram of a fragmentation mechanism of the processing apparatus of FIGS. 1 to 4. [Figure 7] FIG. 5 is a diagram showing a detailed schematic diagram of a fragmentation mechanism of the processing apparatus of FIGS. 1 to 4. [Figure 8] FIG. 5 is a diagram showing a detailed schematic diagram of a fragmentation mechanism of the processing apparatus of FIGS. 1 to 4. [Figure 9] FIG. 2 illustrates in further detail the morselizing mechanism of the present invention. [Figure 10] FIG. 2 illustrates in further detail the morselizing mechanism of the present invention. [Figure 11A] FIG. 11 is a partial top view of a portion of the morsel mechanism of FIGS. 9 and 10. [Figure 11B] FIG. 11 is a side view, partially in section, of the morselizing mechanism of FIGS. 9 and 10; [Figure 12A] 1A-1C show various configurations of blade edges and the relationship of the blades to the shearing plane of the morsel mechanism of the present invention. [Figure 12B] 1A-1C show various configurations of blade edges and the relationship of the blades to the shearing plane of the morsel mechanism of the present invention. [Figure 12C] 1A-1C show various configurations of blade edges and the relationship of the blades to the shearing plane of the morsel mechanism of the present invention. [Figure 12D] 1A-1C show various configurations of blade edges and the relationship of the blades to the shearing plane of the morsel mechanism of the present invention. [Figure 13A] 13A-13C show alternative configurations of the cutting blade of the morselizing mechanism of the present invention. [Figure 13B] 13A-13C show alternative configurations of the cutting blade of the morselizing mechanism of the present invention. [Figure 13C]13A-13C show alternative configurations of the cutting blade of the morselizing mechanism of the present invention. [Figure 14] FIG. 2 is a schematic diagram of a recirculation flow path created using the morsel mechanism of the present invention. [Figure 15A] FIG. 5 is a cross-sectional view of the treatment device of FIGS. 1-4 attached to a preferred embodiment of an applicator. [Figure 15B] FIG. 15B is an exploded view of the applicator of FIG. 15A. [Figure 15C] FIG. 15C is a side view of the applicator of FIG. 15B. [Figure 15D] FIG. 15C is a cross-sectional view of the applicator of FIG. 15B. [Figure 15E] FIG. 15C is a horizontal cross-sectional view of the applicator of FIG. 15B. [Figure 16] 13 is a partial cross-sectional view of a further embodiment of a processing device of the present invention attached to a further embodiment of a separating device and an applicator device. [Figure 17] 13 is a partial cross-sectional view of a further embodiment of a processing device of the present invention attached to a further embodiment of a separating device and an applicator device. [Figure 18] 13 is a partial cross-sectional view of a further embodiment of a processing device of the present invention attached to a further embodiment of a separating device and an applicator device. [Figure 19] FIG. 13 shows a schematic diagram of a processing device in conjunction with a further embodiment of a removable detachment device configured for use as an applicator device. [Figure 20] FIG. 2 is an axial cross-sectional view of a treatment device of the present invention including a baffle for turning a single large vortex into separate smaller vortices for better pulverization of tissue. [Figure 21] FIG. 2 is a transverse cross-sectional view of a treatment device of the present invention including a baffle for turning a single large vortex into separate smaller vortices for better morselization of tissue. [Figure 22] FIG. 2 is a cross-sectional view showing the flow through the treatment device of the present invention recirculating from the treatment device vessel to the exterior. [Figure 23]FIG. 1 is a schematic diagram showing the processing apparatus of the present invention used in conjunction with a centrifuge device to separate and compress particles from a solution. [Figure 24] FIG. 2 is a schematic flow diagram of the system proceeding of the present invention. [Diagram 25] FIG. 1 shows a table showing samples of FTSGP that were processed according to the present invention and showed cell viability of 87.7-98.1% during and immediately after processing using the devices, methods, and systems of the present invention. [Figure 26A] FIG. 1 shows a photograph of a sample of the invention of morselized FTSGP in fluid suspension withdrawn from a processor of the invention as described herein without a baffle after 4 minutes of processing. [Figure 26B] FIG. 13 shows a photograph of a subsequent sample of the invention of morselized FTSGP taken after a total of 7 minutes of processing without a baffle. [Figure 27] FIG. 13 shows a photograph of an inventive sample of morselized FTSGP using the inventive process and apparatus without a baffle after a total of 7 minutes of processing. [Figure 28A] Close-up of a portion of a pre-treatment FTSG, showing a cross-sectional view revealing a thin layer of epidermal tissue (usually containing the pigmented stratum corneum, stratum lucidum, stratum granulosum, cell-dense stratum spinosum, and stratum basale) over a thicker layer of typically white dermis (containing the dermal papilla, stem cell-rich hair follicles, sweat glands, blood capillaries, sensory nerve fibers, sebaceous glands, and other dermal components - all contained within abundant collagen fibers and connective tissue). [Figure 28B] FIG. 1 shows the resulting dense mixture of comminuted FTSGP particles of the present invention suspended in 35 ml of buffer solution contained within the processor chamber. [Figure 28C] FIG. 1 is a magnified view of a densely packed FTSGP tissue particle solution of the present invention presented in a Petri dish. [Figure 28D] FIG. 1 is a close-up of a processed FTSGP of the present invention, annotated to point out that the mixture contains different amounts of epidermis (pigmented) versus dermis (generally whiter), which varies proportionally when viewed in cross-section of the pre-processed tissue. [Figure 29A]28A-28D show samples of abdominoplasty procedures performed on different days and from different patients using the same device and parameters as in FIGS. 28A-28D. [Figure 29B] 28A-28D show samples of abdominoplasty procedures performed on different days and from different patients using the same device and parameters as in FIGS. 28A-28D. [Figure 29C] 28A-28D show samples of abdominoplasty procedures performed on different days and from different patients using the same device and parameters as in FIGS. 28A-28D. [Figure 29D] 28A-28D show samples of abdominoplasty procedures performed on different days and from different patients using the same device and parameters as in FIGS. 28A-28D. [Figure 29E] 28A-28D show samples of abdominoplasty procedures performed on different days and from different patients using the same device and parameters as in FIGS. 28A-28D. [Figure 30A] FIG. 2 shows a harvested cartilage section according to the present invention. [Figure 30B] FIG. 2 shows morselized cartilage according to the present invention. [Diagram 31] 1A-1D are schematic diagrams illustrating the apparatus technology used in accordance with the present invention, including a processing device, an applicator device, and a reusable instrument. [Diagram 32] FIG. 1 is a sequence diagram illustrating the preparation, processing and application employed in accordance with the present invention. [Diagram 33] FIG. 1 illustrates the present invention for full thickness skin grafts and cartilage grafts. [Diagram 34] FIG. 1 illustrates the process employed in the present invention, including introduction, morselization and distribution. [Diagram 35] FIG. 1 illustrates variable tissue particle sizes produced in accordance with the present invention, including full thickness skin graft particles containing cells and extracellular connective tissue. [Diagram 36] FIG. 2 illustrates distribution options that may be employed in accordance with the present invention. [Figure 37] FIG. 1 shows examples of clinical indications of the present invention. [Figure 38] FIG. 1 illustrates the current development status of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The device includes features that optimize the viability of processed cells and the convenience of handling and transferring tissue. Specifically, aqueous processing allows for temperature, pH, and salinity control of the process, which ideally varies depending on the tissue, tonicity factors. pH can be controlled with physiological buffers. Variable blade speed allows for control of potential barotrauma caused by the formation of a vortex, which repeatedly moves tissue suspended in an aqueous medium through the cutting device.

[0031] The selection of an ultra-sharp cutting blade is one of the key factors in ensuring that the minced tissue remains viable. The ability to control the temperature of the medium during processing, as well as the use of a pH-controlled aqueous medium over time, are also important factors in achieving the very high viability of the present invention.

[0032] Mass produced disposable razor blades and microtome blades are among the sharpest steel blades in the world. Razor type blades are typically martensitic stainless steel with a chromium composition of 12-14.5% and a carbon content of about 0.6%. The high volume linear process for producing such blades starts with roll-formed strip of controlled thickness and runs as ribbon through a continuous manufacturing process. The linear manufacturing process allows for very tight and repeatable control of multiple sequenced automated processes including, for example, grinding multiple clearly stepped chamfered / faceted cutting blade edges on both sides, resulting in cutting edges as thin as 30 nm for razor blades and 3 nm for microtome blades, applying enhanced hardening coatings (e.g. titanium + artificial diamond hardening the edges) in separate vacuum chambers, followed by, for example, a low friction polymer film for a more slippery edge. The individual blades are die stamped stepwise in-line in a repeatable manner.

[0033] Blade sharpness is absolutely necessary to minimize cell mastication. The use of an ultra-sharp blade that passes through and between clumps of live cells and through the interstitial spaces best ensures a narrow margin of breaching cells along the cut line with the least amount of shear force and cell crushing. Slicing of tissue between two blade edges passing at an acute angle allows for stabilization of the tissue throughout each cut, achieving controlled, atraumatic slicing of full thickness skin tissue into morselized particles.

[0034] The use of ultra-sharp blades, achievable through an automated process, ensures reproducibility and expedites the morselization process, allowing for the rapid conversion of autologous full-thickness skin into new morselized transplantable tissue particles within minutes.

[0035] To maintain cell viability, best practice is to keep harvested tissue moist and suspended in a pH-controlled solution (such as saline, buffer, BioLifeSolution™, or other cell growth / storage solution) during handling.

[0036] Detailed description of the device One preferred embodiment for morselizing a sterile fluid supported full thickness skin graft (FTSG) is generally shown in FIGS.

[0037] The processing device 10 includes a fluid-tight container 12 having an open top end 14 that may be suitably enclosed by a cover 16. The cover 16 has an inlet opening 18 to allow for the insertion of tissue into the fluid. In a preferred embodiment, the container is generally cylindrical with a closed curved bottom 20 opposite the open top end 14 and having an outlet opening 17 therein. While the cover 16 and container 12 may be made of a variety of materials, in a preferred embodiment, the cover and container are formed of a suitable plastic, such as polypropylene (PP), polyethylene (PE), polystyrene (PS), polyethylene terephthalate (PET), polyimide (PA), acrylonitrile butadiene (ABS), polyether ether ketone (PEEK), and polyurethane (PU). Combinations or copolymers of these polymers may be used. Glass, ceramic, or metal containers may also be used. The container 12 may be transparent to allow visualization of the processing and quality of the fluid and tissue being processed therein.

[0038] An additional removable or adjacent protective cover that can be manually opened and closed can be included to close the cover opening during processing to best ensure containment of fluid and cellular contents.

[0039] It is also contemplated that all components that make up the overall processing device, including the container and morsel mechanism, separator, and applicator, can be packaged and bulk sterilized for single patient use and disposable. The packaged device can be irradiated with gamma radiation or electron beam or ethylene oxide (EtO). Alternatively, the processing device may be sterilizable and reusable.

[0040] Extending from the bottom 20, the vessel 12 includes a generally elongated tubular conduit 22 that is in fluid communication with the interior 13 of the vessel 12 via the opening 17. The conduit terminates at its lower end in a vessel mount 24. Extending in fluid communication outwardly from the conduit 22 is an outlet 26 which, in the preferred embodiment shown in Figure 1, extends perpendicular to the conduit 22. An explanation of the purpose of the conduit 22, the vessel mount 24 and the outlet 26 will be explained in more detail below.

[0041] The cover 16 is movably supported at the open top end 14 of the container 12 for movement along a central axis A. The top end 14 of the container 12 includes an outwardly facing key 12a that seats in a slot 16a of the cover 16, for example, adjacent a skirt 16b. The key 12a is movable along axis A in the slot 160, allowing movement of the cover 16 relative to the container 12 while restricting rotation of the cover 16 about axis A.

[0042] The cover 16 further includes an inwardly formed, downwardly extending, generally tubular stem 28 having an upper cup-shaped cavity 30 covered by a cap 31. The stem 28 receives a mounting rod 32 having a threaded lower end 34 and an upper end 36 terminating in an enlarged head 38. The head 38 is restrained within the cavity 30 by a spring 39 supported by, for example, one or more Belleville, dome, wave washers or washers restrained between the lower end of the cavity 30 and the enlarged head 38. The spring or springs 39 may be further restrainingly sandwiched between washers 39b of a conventional type, and the threaded lower end 34 of the rod 32 is threaded into the impeller 108 about the axis A. A shoulder 32b adjacent the threaded end 34 of the rod 32 rests against the impeller 108.

[0043] A disk-shaped fixed cutting member 102 is supported on the end of the stem 28 in a plane perpendicular to the axis A. The fixed cutting member 102 is restrained from rotating about the axis A by, for example, a mating pin 28a or other keyed feature that engages between the stem 28 and the fixed cutting member 102.

[0044] Here, as best shown by Figures 1-4 and 9-10, the subassembled rod 32, head 38, impeller 108, and blades 112 are captured together and configured to rotate about axis A relative to the stem 28. One or more springs 39 between the head 38 and the lower end of the cavity 30 act to lift the head 38, and thereby the stem 28 and impeller 108, up and through the stem 38 to continuously restrain the rotating blade edges 112a in compression against the fixed cutting member 102.

[0045] With particular reference to Figures 5-11B, the subassembly of rotating impeller 108 with associated rotating blades 112 is compressively held against fixed cutting member 102 about axis A by rod 32 with head 38 and lower end 34 and spring 39 passing through stem 28, collectively referred to as the morsel mechanism.

[0046] As described in further detail below, the drive shaft 42 is attached to an operable processor 44, shown generally in FIG. 1, via a drive engagement 46 at the lower end of the drive shaft 42. The processor 44 causes rotation of the drive shaft 42, thereby causing rotation of the rotating blade 112 relative to a fixed blade edge 122 in the morselizing mechanism 40, which causes morselization of the tissue, or specifically the FTSGs, within the container 12. Suitable rotating shaft seals 47 and 41 provide a fluid seal between the drive engagement 46 and the drive shaft 42.

[0047] The processor 44 is preferably a reusable device configured to be easily aseptically cleaned after each use. The processor 44 is also configured to interchangeably receive the processor 10 in mechanical engagement in a manner that allows a user to attach, use, and remove the processor using standard methods for interfacing surgical devices in a sterile field. The processor 44 may also be configured to receive a sterile drape to isolate surfaces not covered by the coupled processor. The processor may also be a device that is readily available in an operating room setting, fully sterilizable, and / or powered by compressed air.

[0048] 2 and described in more detail below, rotation of the impeller 108 provides a continuous circulating flow (CF) of fluid and contained tissue or particularly FTSG around the interior of the vessel 12 and through the morselizing mechanism 40, continually cutting the FTSG into smaller particles. The morselizing mechanism 40 seats in fluid-tight relation over the outlet opening 17 of the open bottom 20 of the vessel 12 to maintain the FTSG and fluid within the interior of the vessel 12 throughout morselization. A suitable seal 19 provides a fluid seal between the morselizing mechanism 40 and the outlet opening 17.

[0049] 3 and 4, the drive shaft 42 can lift the morsel mechanism 40 out of the opening 17 in the open bottom 20 of the container 12. Upward movement of the drive shaft 42 along axis A causes upward movement of the cover 16 relative to the container 12, with the keys 12a riding in the slots 16a. This lifts the morsel mechanism 40 from its sealed position on the bottom 20 of the container 12, thereby providing an accessible exit opening 17 for fluid flow.

[0050] Shredding mechanism The operative components of the morsel mechanism 40 are shown in further detail with further reference to FIGS.

[0051] The morselizing mechanism 40 includes a base component 100 and a stationary cutting member 102 axially aligned with one another along axis A. The base component 100 is attached to the drive shaft 42 with a depending mount 104 to provide rotation. Above the mount 104 is a generally transverse flat circular plate 106. The plate 106 also serves as a seating surface at the opening 17 in the bottom 20 of the container 12, as shown in Figures 1-4.

[0052] The upper end of the base component 100 functions as an impeller 108 having two or more impeller vanes 110 extending upwardly from the plate 106 on diametrically opposite sides of the axis A. The impeller vanes 110 are each complementarily curved along the axis A for purposes described in more detail below. Each impeller vane 110 supports a cutting blade 112 at its upper end in facing relationship. Also, as described in more detail below, the cutting blade 112 at the upper end of the impeller vane 110 is supported in juxtaposition with the fixed cutting member 102. The blade 112 rotates with the base component 100 relative to the fixed cutting member 102.

[0053] In the preferred embodiment shown in Figures 5-8, the stationary cutting member 102 has a generally disk-shaped body 102a. The body 102a defines circumferentially disposed, spaced apart blade surfaces 120. Each blade surface 120 includes a pair of converging blade edges 122 that converge at an apex 122a. A breech 124 is defined between each blade surface. The breech 124 is an open space between the blade surfaces that allows passage of TPs, such as FTSGs and other TPs, and fluid passing through the body 102a as the base component 100 rotates.

[0054] In one embodiment, shown in Figures 7 and 8, the fixed blade edge 122 is defined by longitudinally radially extending members 123 that converge with the arc of a circle that forms the outer edge of the disk-shaped body 102a.

[0055] 5 and 6, the blade surface 120 is formed into a teardrop shape with the apex 122a of the converging blade surface 120 converging in a tapered curve near the circumference of the fixed cutting member 102. This shape has been found to aid in promoting complete morselization of tissue, particularly the TPs that have passed through.

[0056] The positioning of the fixed cutting member 102 relative to the impeller 108 is shown diagrammatically in Figures 9-12. A small clearance space (S) is provided between the lower edge of the fixed cutting member 102 and the upper end of the impeller 108, such that the extending rotating cutting blade 112 is supported in apposition against the lower edge of the disc-shaped body 102a of the fixed cutting member 102. This creates a shearing plane (SP) along which tissue is sheared into morsels.

[0057] The fixed cutting member 102 is preferably stainless steel and CNC machined with a fixed blade edge 122 that is precision ground and free of sharp burrs. The surface of the bottom shearing surface (SP) should be flat, preferably with a finish of 0.08 μm or better. The stainless steel material may generally be a corrosion resistant and hardened grade, e.g., 440C stainless steel that is machined in the annealed condition and vacuum heat treated to 55-60RC to achieve a hardened surface and durable sustainable cutting edge. The fixed cutting member 102 may alternatively be of other non-corrosive materials or of alternative hardness or may be made by other precision processes. The rotating cutting blade 112 juxtaposed with the fixed cutting member 102 in compression engagement may be of different materials, e.g., plastic or ceramic, different hardness, or have alternative treatments or applied surface finishes to optimally avoid wear and galling conditions as the opposing surfaces slide against each other along the shearing surface (SP). Additionally, the blade edge 122 of the stationary cutting member 102 and / or the blade edge 112a of the rotating cutting blade 112 may be formed to be sharpened or subsequently sharpened.

[0058] The rotating cutting blade 112 may be attached to the upper end of the impeller 108 supported by a spring, such as an elastomeric pad 130, which biases the edge of the cutting blade 112 against the lower edge of the disc-shaped body 102a of the fixed cutting member 102. It has been found that by maintaining the cutting blade edge 112a in physical contact against the fixed cutting member 102, tearing and shredding of tissue is minimized.

[0059] 5 and 6, the fixed cutting member 102 may have two or more breeches 124, preferably three as shown, radially arranged about the axis A, each with an associated blade edge 122. The rotating base component 100 may similarly have two or more cutting blades 112, preferably two as shown, radially arranged about the axis A. However, the amount of rotating blades 112 is best varied from the amount of fixed blades 122 to maximize cutting efficiency by minimizing cumulative cutting forces that would be compounded if multiple blades were engaged simultaneously.

[0060] The rotating cutting blade 112 is positioned at an acute cutting angle relative to the apposed fixed blade edge 122 such that tissue is cut with a slicing action when captured between the rotating blade 112 and the apposed fixed blade 122.

[0061] FIG. 12A shows that the cutting edge 112a of the rotating blade 112 can be manufactured with a ground double bevel edge. Double bevel refers to both sides of the blade being beveled. Alternatively, as shown in FIGS. 12B and 12C, the cutting edge 112a can be sharpened with a secondary distal ground double bevel edge that further maximizes sharding of the TFSG. Honing refers to a more precise abrasive grinding or lapping process in which a relatively small amount of material is removed from the surface by finer grit abrasives. The cutting blade 112 used in our functional proof-of-principle system preferably utilizes a secondary ground double bevel edge, as well as an even sharper blade with additional finely ground double bevel edges, such as a set of three graduated double bevel edges.

[0062] The rotating cutting blade 112 is best positioned at an acute angle relative to the underside of the fixed cutting member 102 so that the tip of the rotating blade cutting edge 112 a passes at an acute angle relative to the fixed blade edge 122 of the blade face 120 .

[0063] As previously discussed, the spring 39 can be used to compressively preload the rotating blade edge 112a to maintain contact with the fixed blade edge 122 during rotation. FIG. 12C illustrates that the cutting edge 112a of the rotating blade can flexibly conform under preload against the shearing surface (SP), particularly if the cutting blade 112 is substantially rigid, e.g., about 0.010 inches thick. Additionally or alternatively, as shown in FIG. 9, the cutting blade 112 itself can flexibly conform under preload against the shearing surface (SP), particularly if the cutting blade 112 is substantially flexible, e.g., about 0.003 to 0.006 inches thick.

[0064] 12D illustrates an embodiment in which the blade edge 112a of the rotating blade 112 may be formed to have a flat or planar area 112b that is flush or coextensive with the blade edge 122 of the stationary cutting member 102 at the shearing plane (SP).

[0065] In a preferred embodiment, the shear plane (SP) is perpendicular to the chamber impeller and blade rotation access. The shear plane (SP) can also have other orientations relative to the axis A. An example is shown in FIG. 13A, which shows a bushing 200, a rotating seal 210, a stator 220, a rotor 240, and a cutting chamber 260. The blades 242 of the rotor 240 pass closely behind the blades 222 of the stator 220, which are fixed blades about the central axis A.

[0066] Also in this embodiment, the rotor blades 242 have surfaces configured as integrally formed impeller vanes. The rotating edges may be generally coextensive with the leading impeller vane edges. It is desirable for the rotating rotor blades and the fixed stator blade edges to be in close physical contact to best achieve precise slicing. The blades may be mechanically polished for a tightly controlled minimum shear gap, preferably less than 30 micrometers. Placing the rotating blade edge at an acute angle to the shear surface of the fixed cutting blade edge facilitates shear cutting of the impinging tissue. Maintaining a spring-assisted compressive engagement between the rotating blade edge and the shear surface of the opposing blade edge best ensures that the tissue is precisely sliced ​​rather than slipping between the converging blade edges.

[0067] Other techniques and configurations for cutting tissue with shearing surfaces would also be within the purview of one skilled in the art.

[0068] Tissue mincing Having described the basic components of the process apparatus 10 of the present invention, one preferred example of morselization of tissue, or specifically TP, as defined herein, will now be described with reference to the figures.

[0069] 1-4, the FTSG, prepared as described above and in a fluid medium, may be inserted into the container 12 through the inlet opening 18 of the cover 16. A fill line F may be provided to provide guidance regarding the amount of tissue and fluid that may be placed into the container 12. Thereafter, a rotation mechanism connected to the drive engagement portion 46 is actuated to rotate the drive shaft 42 and morsel mechanism 40.

[0070] 2, such rotation induces a circulatory flow of tissue through the fluid by establishing a vortex within the vessel 12. The vortex provides for a continuous movement of the tissue through the morsel mechanism so as to thoroughly morselize the tissue contained therein. The circulatory flow path and established vortex are created by the configuration of the impeller vanes 110 of the impeller 108.

[0071] As shown diagrammatically in FIG. 14, the impeller vanes 110 provide an axial thrust with the upper or front portion 110a of the impeller vane 110 on the fluid and contained tissue or specifically the FTSG, and a radial thrust with the lower or end portion 110b of the impeller vane 110. The structure of the impeller vanes 110a and 110b allows for the continuous movement of the FTSG throughout the vessel 12. The impeller 108 drives the fluid containing the FTSGP through the breech 124 of the fixed cutting member 102, passing between the rotating blade 112 and the fixed blade 122, and then deflecting it against the trough-like bottom 20 and the sidewall of the vessel 12, reversing the flow. In the opposite direction of flow, it circulates through the peripheral volume (PV). The fluid flow then transitions into a vortex to mix the tissue, drive it through the central volume (CV), and return again through the morselizing mechanism 40, where the FTSG are continuously and repeatedly cut and morselized.

[0072] One skilled in the art can, for example, alternatively configure the impeller vanes and / or internal vessel shape and / or configuration of bottom 20 to enhance effective circulatory flow of the fluid having suspended tissue through morselization mechanism 40 throughout vessel 12. Internal flow characteristics can be enhanced, for example, by increasing or decreasing the pitch or otherwise reshaping impeller vanes 110, or by increasing or decreasing the pitch of the portions of vanes configured for axial thrust 110a relative to the pitch of the portions of vanes configured for radial thrust 110b, or by eliminating either axial or radial thrust vane surfaces.

[0073] 3 and 4, once TP, such as FTSG and other tissue particles described herein, are fully comminuted, the drive shaft 42 can be raised to remove the impeller 108 from its seated position within the vessel. The plate 106 is displaced from the opening 17 which establishes fluid communication with the conduit 22 and the outlet 26. The comminuted tissue is discharged by a gravity driven drain through the outlet 26 for use in the manner described below.

[0074] Once morselization of the FTSG or other tissue graft into TP is complete, rotation of the impeller 108 can be stopped and the TP, as defined herein having a specific gravity greater than water, will settle to the bottom 20 of the container 12. Those skilled in the art will recognize that alternative methods can be used to manually withdraw the settled TP from the bottom 20 of the container 12 within the processing device 10. For example, the settled TP can be withdrawn into a conventional syringe in combination with an elongated cannula tip (not shown) that can be inserted into the container 12 through the inlet opening 18. In such a manner, the same syringe used to withdraw the TP from the processor 10 can then be used as the application device. In this manner of manually withdrawing the TP through the inlet opening 18, the processing device 10 need not include a drain 39 or an outlet 26.

[0075] Discharge of fragmented FTSGP The release of morselized tissue particles (TP) or, for example, specifically FTSGP, into an applicator 300 can now be described with reference to Figures 15A-15E. With reference to Figure 15A, an applicator 300 that can be used to collect and dispense TP is typically configured as a syringe, which provides a well-known means for delivering and metering a controlled amount.

[0076] The syringe applicator 300 also functions as a device for separating excess fluid from the TP. A cylindrical screen filter 302 is formed as an insert into the applicator body 303 and has an internal applicator chamber 308 lumen for receiving the plunger 304 and piston 306. A peripheral drain channel 305 can surround the filter 302 to allow excess fluid in the morselized TP to pass freely through the filter wall, through the drain channel 305, and out the drain outlet 310. The screen filter can encompass 360° of the applicator, or only a portion of it, as shown in FIG. 15A, leaving enough area to view the contents through the window 307. The filter 302 can be a fine mesh with, for example, 50 micron openings that allow fluid to pass while still containing the TP. Alternatively, the filter 302 can be constructed from, for example, laser cut, woven mesh, or acid etched perforated screen with larger openings of a specific size to selectively contain wet particles larger than the utilized filter openings while expelling smaller particles with the solution. Syringe applicator 300 can also be configured to separate liquid from the TP and dispense the TP, for example, onto or into a separate device or container for application to an attached syringe.

[0077] FIG. 15A also shows that the treatment device 10 is attached to the processor 44, for example, using a bayonet mount 115. The treatment device 44 may be cordless and may include a low voltage DC motor 114 powered by an included rechargeable battery. The battery is preferably recharged by connecting to a remote ACDC charger. The low voltage DC motor may also be powered via a remotely connected ACDC power source. In both such methods, the use of low voltage DC power allows for safe use of the treatment device 10 in the potential presence of aqueous solutions. An axially connected drive engagement 46 connects the motor shaft of the processor 44 to the central shaft assembly. During morselization of the TP, the motor 114 may be automatically slowed or stopped and raised to open the seal 19 under the impeller, allowing the morselized tissue mixture and solution to drain from the treatment chamber through the outlet 26 via the gravity driven drain 39 and enter the applicator 300 via the port 320.

[0078] The applicator 300 is shown with the plunger 304 and piston 306 in their raised positions and the cap 318 in place, closing the dispensing orifice. Once the TP and solution have entered the applicator 300, the fluid is expelled from the TP as it passes freely through the filter wall 302, exits the applicator 300 through the flow channel 305, and enters the fluid waste drain container 317 through the drain outlet 310. The plunger 304 can then be advanced sufficiently into the applicator chamber 308 to allow the piston 306 to close the port 320. The applicator 300 can then be removed from the processing device 10 by disconnecting the inlet port 320 of the applicator 300 from the outlet port 26a of the processing device 10. The cap 318 can then be removed from the applicator 300 and a selected applicator tip 301 can be attached to the dispensing orifice 309 for dispensing the TP in a manner described in more detail below.

[0079] A further embodiment of the invention shown in Figure 16 is similar to Figure 15A in that it includes a treatment device 10 mechanically coupled to a processor 44. Drive engagement 46 can similarly rise to open seal 19 and discharge vessel 12 through outlet 26, but as shown in Figure 16 (and various previous Figures 1, 2, 3), drive shaft 42 may include a rotor pump 118, for example with fins integrally molded thereon. Rotor pump 118 is driven by motor 114 via axis A to circulate solution through separation device 415.

[0080] 16 introduces a different separation device 415 that circulates fluid from the processing device 10 through the outlet 26 and inlet 29 conduits. Once pulverization of the TP is complete, the motor 114, along with the drive engagement 46 and drive shaft 42, automatically rises, opening the chamber seal 19 beneath the impeller 108 and expelling the fluid and TP from the vessel 12.

[0081] The motor speed is varied as necessary to pump the solution and TPs through the outlet channel 26 and diverter valve 417 into a cylindrical separation chamber 416 containing a cylindrical filter tube 402 lining. The filter tube 402 may be, for example, a woven mesh, a perforated film, or an acid-etched screen with appropriately sized openings to specifically capture TPs of a desired size. The particles are captured within the separation chamber 416 as the fluid passes through the filter tube and through the circumferential drain channel 405, exiting the separation device 415 through the inlet conduit 29 and returning to the vessel 12 of the processing device 10. Within a few short passes, the motor 114 automatically stops as the TPs are substantially flushed from the vessel 12 and transferred to the separation device 415.

[0082] The diverter valve 417 can then be automatically or manually switched, for example rotated 90° clockwise, to open a fluid path from the separation chamber 416 to the applicator 400. The inlet conduit 29 is positioned below the fill line (F) of the container 12 to allow the head pressure of the contained fluid to substantially flush the TP from the separation chamber 416, through the diverter valve 417, through the applicator attachment 411, and into the applicator chamber 408 of the removable applicator 400.

[0083] Thereafter, diverter valve 415 is closed, applicator 400 is detached from applicator attachment 411, and a plunger with a piston (e.g., as shown previously in FIG. 15B) is manually inserted into the lumen of applicator 400. Cap 418 is removed (e.g., with a Luer-type connection) and replaced with a selected applicator tip (e.g., as featured in FIG. 15B). Applicator 400 is then ready to dispense TP to the desired autograft target in a manner described in further detail below.

[0084] The processing device 10, separation device 415 and applicator 400 may be packaged as an integrated sterile assembly, or alternatively, the applicator 400 may be separately sterile packaged.

[0085] Turning now to FIG. 17, a further embodiment of the processing device 10 with processor 44 and applicator 500 is shown here coupled to a different type of separation device 515. In this embodiment, pump 118 similarly pumps the solution in which the pulverized FTSGPs are suspended from vessel 12 through outlet 26 and back through inlet 29, which in this configuration is in fluid communication with separation chamber 515, which separates the TPs from the solution using cyclonic action. This system uses the principle of terminal settling velocity of solid particles in a centrifugal field. Outlet 26 from processing device 10 enters tangentially into separation chamber 516 of separation device 515. The high velocity centrifugal field in the hydrocyclone rapidly moves the particles to the outer wall of conical chamber 516, forcing them through valve 517, through applicator attachment 511, and down the inside of the conical wall into applicator 500. Valve 517 is then closed, applicator 500 is disconnected from the collector, a plunger with a piston is inserted into applicator 500, and applicator cap 518 is replaced with the selected dispensing tip, and the applicator is ready to dispense method TP as described below.

[0086] Yet another embodiment in which the processing device 10 is coupled to a processor 44 is shown in FIG. 18. In FIG. 18, the inlet 20 and outlet channels 26 are shown in fluid communication with a separation chamber 616 that uses a whirlpool-like action to collect the swirling TP particles toward a central drain through which concentrated TP is deposited in an applicator chamber 608 within an applicator 600. As with the above embodiment, the valve 617 is then closed, the applicator 600 is disconnected, and the applicator cap 618 is replaced with a selected dispensing tip. The applicator 600 is then ready to dispense TP in a manner described in more detail below.

[0087] Yet another embodiment is shown in FIG. 19, where the processing device 10 is similarly coupled onto a separation device 716 via the outlet 26 and inlet 29 as shown in FIG. 16. Also similar to the embodiment of FIG. 16, the separation device 716 includes a separation chamber 716 separated from one or more drain channels 705 by a filter tube 702 such that solution passing through the separation chamber 716 passes through the filter tube 702, through the drain channel 705, and through the inlet 29 for recirculation through the processing device 10. However, in this embodiment, the outlet 26 and inlet 29 may include a sealable, closable port 720 (not shown) such that the separation device 716 may be removable from the processing device 10 while containing fluid from leakage from the removable outlet 26 and inlet 29 flow paths. In this manner, the removed separation device 716 may include the plunger 704 and piston 706 as well as the removable cap 718, which together may be used as an applicator 700, as similarly described in FIGS. 15C and D.

[0088] The recirculating flow (CF) paths depicted diagrammatically in Figures 2 and 14 have been significantly simplified by not showing the turbulent eddy vortices to more clearly show the recirculating nature of the fluid flow pattern. Early prototypes revealed that while the impeller-induced vortices were desirable to continually recirculate and mix the TP suspended in the fluid, they also caused the particles to make a longer circuitous path around the vessel 12 than necessary before being drawn through the fragmentation mechanism 40.

[0089] The axial view of FIG. 20 and the side view of FIG. 21 introduce preferred improvements to the processor 10 to better morselize the TP. The arrangement of vertical baffle panels 140 radiating from the stem 28 effectively breaks down a single vortex. The baffles are positioned proximate to the apex of each set of converging blade edges 122 on the stationary cutting member 102. The swirling fluid within the vessel 12 bounces off each baffle 140 and creates a separate smaller vortex V adjacent each baffle 140. The smaller vortexes V better carry the TP through each of the successively closing breaches 124 of the morselization mechanism 40.

[0090] The circulation flow (CF) paths within the processing device 10 depicted in Figures 2 and 14 represent preferred embodiments (and are included in other figures, by way of example), but are not intended to limit the scope of the invention. Although the impeller 108 is used to continuously recirculate the fluid and TP through the central volume (CV) of the vessel 12 so that they pass repeatedly through the morselization mechanism, the fluid and TP do not necessarily have to be recirculated through the peripheral volume PV on their return. Thus, Figure 22 teaches that the fluid and suspended TP may be recirculated through the morselization mechanism 40 in other ways, such as, by way of another example, through the recirculation conduit 150 and out of the vessel 12.

[0091] Additionally, while FIG. 22 illustrates rotor pump 118 integral to shaft 42 and rotating about axis A, those skilled in the art will recognize that a fluid driven pump may alternatively be included elsewhere along recirculation conduit 150 between outlet 26 from processing device 10 and return inlet 29 to processing device 10. Additionally, as such, the circulation pump (not shown) need not be driven by or associated with the motor also used to drive processor 10, but may be, for example, a separately operable fluid pump. Additionally, and with further reference to FIG. 22, such recirculation conduit 150 may include one or more diverter valves 117 such that (upon completion of mortarization) the fluid and suspended TP may be diverted to circulate through any of the various types of separation devices, for example, as described in FIGS. 15A-15E, 16, 17, 18, or 19.

[0092] 22 used in a system configured with a recirculation conduit 150 external to the vessel 12 of the processing device 10 need not have vanes configured for radial thrust 110b. In such an embodiment, vanes having a pitch configured for axial thrust 110a only may be sufficient on the impeller 108 to facilitate circulation of tissue supporting solution from the vessel 12 along axis A, through the outlet channel 26, through the recirculation conduit 150, through the inlet channel 29, and continuously recirculated by the morsel mechanism 40 within the vessel 12.

[0093] Yet another embodiment is shown diagrammatically in FIG. 23. Here, a processing device 910 is shown used in combination with a centrifugal type separation device 919 to effectively separate and compress the processed TP, as defined herein, for dispensing via a conventional syringe (not shown). The separation device 919 may be covered within a protective cover 976. The processing device 910 and separation device 919, together with the enclosing shroud 976, can be preferably integrated into a single unit and pre-sterilized for use as a disposable device packaged for a single patient use and as red bag medical waste. The device can be used multiple times within an individual patient treatment. The combined processing device 910 and separation device 919 are axially aligned and configured to be fixably coupled, for example, with a bayonet engagement 960, onto a sterilely washable reusable processor 944.

[0094] Once pulverization of the TP in the processing device 910 is complete, the TP is discharged into solution through a drain 939 from the bottom 920 of the vessel 912. The drain 939 is preferably positioned about the central axis A of the processing device 910 or otherwise suitably located at the bottom 920 of the vessel 912 so as to be in fluid communication with the central chamber 972 of the centrifuge device 919.

[0095] One or more individual collection chambers 973 project radially from the central chamber 972, each collection chamber having a distal exit orifice 974. The distal exit orifice 974 has a standard threaded female Luer engagement for interchangeable attachment of a standard Luer cap 975 or a standard Luer-tip syringe (not shown).

[0096] The central chamber 972 and radially extending collection chambers 973 may be integrally formed as hollow injection blow molded parts, may be manufactured as an assembly of injection molded parts, or may be manufactured as a combination, for example, with an injection molded luer fitting attached to an injection blow molded unibody core.

[0097] The centrifuge 919 is configured to rotate at high speeds, e.g., up to 300 G, on precision radial-type ball bearings (not shown) about an axis that is preferably coincident with or axially aligned with axis A of the processing device 910. The spinning separation device 919 is preferably encased in a protective shroud 976. If the processing device 910 and the centrifuge 919 rotate about the same axis, the inner shaft diameter of the ball bearings may be large enough to allow independent rotation of the centrifuge 919 relative to the rotation of the impeller 908 in the processing device 910.

[0098] After just a few minutes of centrifugation, the TP suspended in the solution separates and becomes compressed within the radially extending collection chamber. The luer cap 975 on the distally extending female luer connector 974 is then unthreaded and replaced with an appropriately sized standard syringe. The compressed TP is then drawn into the syringe, and the filled syringe is removed from the separation device 919 and a selected luer fitting applicator tip (e.g., as previously described in FIG. 15) is attached, ready for autologous TP application.

[0099] Fragmented particles The solutions of suspended TP or particularly FTSGP or other tissue particles described herein may be combined and mixed with other FDA approved additives, such as handling (i.e., saline, buffer, or BioLife Solution™, or other cell growth / preservation solutions, etc.). The mixture can be created in the processing device 10 using vortex circulation to achieve a heterogeneous mixture of debris composed of naturally connected cells and extracellular matrix material. Alternatively, some suspensions / dispersions of TP may be homogeneous. Whether the dispersion or emulsion produced is homogeneous or heterogeneous may depend on many factors, including, but not limited to, the type of tissue, the medium in which it is suspended, the speed and temperature of the process, among other factors. An important advantage of the methods of making the TP suspensions / dispersions of the present invention, as well as the resulting suspensions / dispersions themselves, relates to high cell viability during and immediately after processing to achieve morselization. This ability to morselize while maintaining such high cell viability, as described herein, is unique to the present invention and is not achieved by conventional methods. The methods described herein produce suspensions or dispersions containing TPs with at least 50% viability immediately after treatment, or at least 60% viability immediately after treatment, or at least 70% viability immediately after treatment, or at least 80% viability immediately after treatment, or at least 85% viability immediately after treatment, or at least 90% viability immediately after treatment, or at least 92% viability immediately after treatment, or at least 94% viability immediately after treatment, or at least 96% viability immediately after treatment, or at least 97% viability immediately after treatment, or at least 98% viability immediately after treatment, or at least 99% viability immediately after treatment, generally in real time at the patient's bedside. Generally, processing may take about 1 hour, but preferably less than 1 hour, e.g., 45 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, or 10 minutes or less.

[0100] The TP can also be centrifuged to vary the density, viscosity, and consistency of the tissue particles. This may be desirable for alternative surgical applications. By adjusting the centrifugation speed and time of centrifugation, the shape of the resulting output tissue particles can be customized, e.g., the consistency and density appear as a solution, paste, or cream. Desirably, the resulting output (Id.) is flowable and / or easily applied by diffusion. The resulting output may be further presented, e.g., as a compacted tissue form, or may be further spun and presented as compacted cellular material.

[0101] The TPs as defined herein may be most efficiently delivered from a variety of fluid dispensing devices, particularly syringes, which are well known and useful for easily metering controlled amounts. The particle sizes of interest pass freely through the lumen of a standard Luer connector as a fluid composition. The tips may be interchangeably attached to the applicator, for example, using a standard Luer thread. A variety of interchangeable applicator tips may be included in a dispensing kit for selection as is most appropriate for a particular application at the surgeon's choice for a given procedure. In cream, paste, or liquid form, the TPs, for example, FTSGPs, may be dispensed from a syringe through applicator tips of various selected tip types. The tips may have a narrow / long sector-shaped exit orifice for spreading over a large area. Such sector-shaped tips may be constructed of flexible low durometer silicone or thermoplastic elastomers and may have thin flexible edges, making them useful for gently and evenly spreading the TP over large and / or irregular wound surfaces, for example, burns.

[0102] In dense form, the TP of the present invention can be spread or applied over an area or gap, for example, with a spatula. In dense form, the TP, for example, cartilage particles (CP), can be used as a filler, for example, for cartilage defects. Thus, the TP, such as CP or other tissue particles defined herein, can be mixed with fibrin glue, autologous platelet-rich plasma, growth factors or other FDA approved materials, for example, as a binder. The cartilage or organ TP can also be delivered via an attachment of an endoscope syringe.

[0103] Partial thickness skin graft particles in fluid, cream or solution form may alternatively be dispensed from a syringe through a flexible cannula or needle for subcutaneous application, e.g., to fill cosmetic defects. To deliver the various TPs as described, the lumen may range, for example, from 22 to 18 gauge, or most notably, 22 or 21 gauge.

[0104] In highly soluble forms, the TP may be of lesser variety and sprayed over a large area, as described herein in such cases. In the case of TP for use on burns or open wounds, non-adherent surgical wound dressings can be used to prevent migration of the applied TP while keeping the wound site moist and protected from infection. Such commercially available dressings include, for example, commercially available Drotex, Sofsorb, Carginate, or Aquasorb dressings.

[0105] Systems Methodology The system of apparatus has been described to perform a process in a systematic order. In addition to FIG. 24 showing the progression of the system in operation, the system and process includes: 1) introducing and morselizing tissue into tissue particles in a solution using a processing device 950; 2) then separating the morselized tissue suspended in the solution from the prevailing solution for distribution using a separation device; and 3) then distributing and applying the collected morselized tissue surgically using an applicator device 952. Thus far, several alternatively configured apparatus and methods have been described that employ non-limiting details for accomplishing a three-step process to achieve a desired result.

[0106] The processor device can be used in combination with various types of separation devices. For example, the separation device can take the form of a device that includes a filter tube through which a solution flows to separate tissue particles, as described in Figures 15A-15E, 16 and 19, or a separation device that utilizes a cyclone action in a chamber to separate tissue particles, as described in Figure 17, or a device that uses a whirlpool action in a chamber, as described in Figure 18, or a device that functions as a centrifuge, as described in Figure 23, or the tissue particles can simply be separated by sieving the preponderance of the solution through a screen (not shown), or the settled tissue particles can be extracted from the solution using a standard syringe, or any number of other methods can be contemplated to separate the tissue particles in the solution from the preponderance of the solution.

[0107] The processor device may also be used in combination with various types of applicator devices, for example, the applicator device may be a standard syringe, or a separation device may be further deployed for use as an applicator, as described in Figures 15A-15E or 19, or a spatula may be used to manually apply the tissue particles, or tissue particles in suspension may be sprayed onto large wound areas, or any number of other methods may be used to deliver and apply the tissue particles in a controlled manner.

[0108] FTSG process validation study Full thickness skin grafts (FTSGs) harvested from human abdominoplasties were prepared according to the methods disclosed herein and using the devices and systems disclosed herein.

[0109] Harvested sample FTSGs of various note sizes were each individually placed into a fabricated experimental test apparatus modeled as generally described in Figures 1-4 without baffles and Figures 20-21 with baffles. The processing apparatus was filled with 35 ml of buffered saline solution that had been pre-chilled with ice chips. The FTSGs were then shredded at ambient room temperature of 70°F by subjecting the samples to a slicing speed of approximately 550 rpm for durations that increased incrementally in minutes. Initial testing indicated that there was only a slight temperature rise in the chilled buffered saline solution over the elapsed time of processing each sample.

[0110] The minced tissue samples were quantitatively evaluated to determine cell viability. Treated FTSGP suspended in solution was transferred into 0.5 ml aliquots using a syringe. The aliquots were kept chilled in chipped ice containers. The supernatant was removed after centrifuging the samples in a 700 RPM centrifuge for 5 minutes. Quantitative cell viability analysis was performed using a standard trypan blue test protocol to stain and count live cells and purple ruptured dead cells. The table included as Figure 25 shows the cell viability test results, which consistently showed 87%-98% viability across multiple exemplary sample lots, processing parameters, and processing times.

[0111] Additional MTT testing yielded similar quantitative results to consistently confirm the reliability of the data. The minced tissue particles were also qualitatively evaluated. The resulting minced tissue particles were suspended in solution, drawn from the processor through a cannula into a syringe, and expelled into a Petri dish to form a shallow pool or puddle on the side of a meter scale. Photographs of the minced FTSGP are shown here, each identified by test sample number, to visually and qualitatively document the relative minced size and particle appearance. As evident in the images, tissue particle size is relatively consistent within each sample. Maximum particle size became progressively smaller as the total processing time increased.

[0112] In an exemplary morselization study, ten sections of whole tissue skin grafts (FTSG), each approximately 12 mm x 6 mm x 4 mm thick, were morselized in an unbaffled processor containing 35 ml of buffer with the blades rotating at approximately 550 RPM. Figure 26A (Test 1b) shows a sample of morselized FTSGP in liquid suspension that was withdrawn from the processor after 4 minutes of processing. The FTSGP in solution was transferred to form a shallow pool in a Petri dish to visualize individual particles. The maximum size of the individual particles typically appears to be approximately 1.5-2.0 mm or less on any axis. The majority of particle sizes appear to be less than 1 mm. Figure 26 shows a subsequent sample extracted after an additional 3 minutes, for a total of 7 minutes. In the second sample, the particles appear to be more densely packed, and the typical maximum particle size appears to have decreased to 1.5 mm or less in diameter.

[0113] In the next exemplary morselization study, still using the same patient tissue, the processing chamber contained three baffles and four (vs. 10) FTSG pieces. Samples were again processed with 35 ml of buffer and 550 RPM. As shown in Figure 27, after 3 minutes of processing, the resulting morselized FTSGP were of similar size and particle density as the previous sample after 4 minutes.

[0114] Other studies not included here have demonstrated that similarly morselized FTSGP is injectable through a 22 gauge needle. The term injectable as used herein is meant to include distribution via a syringe and is not intended to be injected only into the body, but also includes distribution into the body, such as into a wound.

[0115] In the next exemplary morselization study (Test 4a), using the same patient tissue and processing equipment and process parameters, multiple large pieces of tissue approximately 2 cm x 3 cm were inserted into the processor and morselized for 4 minutes. Figure 28A is a close-up of a portion of a FTSG before processing, showing a cross-sectional view revealing a thin layer of epidermal tissue (usually including the pigmented stratum corneum, stratum lucidum, stratum granulosum, cell-dense stratum spinosum, and stratum basale) over a thicker layer of typically white dermis (containing the dermal papilla, stem cell-rich hair follicles, sweat glands, blood capillaries, sensory nerve fibers, sebaceous glands, and other skin components - all contained within abundant collagen fibers and connective tissue).

[0116] FIG. 28B (also Test 4a) shows the resulting dense mixture of morselized particles suspended in 35 ml of buffer solution contained within the processor chamber. FIG. 28C shows a close-up of the dense tissue particle solution presented in a Petri dish. FIG. 28D shows a close-up of the processed FTSGP and has been annotated to point out that the mixture contains different amounts of epidermis (pigmented) versus dermis (generally whiter), which varies proportionally as would be expected when looking at a cross-section of pre-processed tissue. Also, the epidermal tissue (with denser cellular structure) appears to slice more sharply compared to the more fibrous dermal tissue. The epidermal and dermal tissue particles appear to be fairly consistently distributed throughout the mixture.

[0117] Figure 29A was processed using the same equipment and the same process parameters as Figures 28A-D, but on a different day, with abdominoplasty-derived tissue from a different patient. Together, these studies demonstrate a repeatable process that can achieve consistent FTSGP output compared to qualitative appearance and particle size, as well as consistently high quantitative cell viability.

[0118] A similarly sized (slightly larger) single piece of FTSG (approximately 2.5 cm x 4.5 cm) was minced for 4 minutes before taking the photograph in Figure 29A (another sample test 1b). Next, Figure 29B (sample test 1c) was minced for an additional 3 minutes, for a total of 7 minutes. And Figure 29C (sample 1d) was minced for an additional 3 minutes, for a total of 10 minutes. Only a small shallow puddle of the resulting FTSGP is shown in each of these images to better visualize the individual particle sizes. The overall amount of FTSGP processed in this study appeared to be densely packed, similar to the previous study in Figures 28A-D.

[0119] The data in the table of Figure 25 shows the relative consistency and reproducible cell viability output of each FTSGP mixture documented for the exemplary test samples contained in Figures 26A-B, 27, and 29A-E.

[0120] The FTSGP shown in Figure 29C above (Test 1d) and in a subsequent sample (Test 2b) were further centrifuged in 1.5 ml aliquots at 700 RPM for 4 minutes. The resulting tissue morphology, shown in Figure 29D, demonstrates the ability to achieve a fine paste-like mixture that can be dispensed through a syringe, as shown in Figure 29E. Such an FTSGP tissue morphology can be easily applied and dispersed, for example, onto an expansive wound surface.

[0121] Articular Cartilage Process Validation Study Articular cartilage was harvested from the periphery of bovine knee condyles using a 2.5 mm ring curette and then morselized according to the methods and using the devices and systems disclosed herein.

[0122] The harvested cartilage sections shown in Figure 30A (Test 4a on 1 / 16 / 17) ranged in approximate size from about 1.0-2.2 cm in length, 2-2.5 mm in width, and .75-1.2 mm in thickness. The cartilage sections were inserted 3-4 times at a time into 35 ml of buffered saline while the slicing blade was rotating at approximately 550 RPM in the morsel mechanism in the apparatus previously described in Figures 1-4 without baffles. The cartilage tissue explants were morselized for a total of 15 minutes at room temperature.

[0123] The resulting cartilage chips are shown in FIG. 30B, demonstrating the ability to finely morselize articular cartilage within the device and by the process described herein to similarly process full thickness skin graft tissue.

[0124] Further details of the invention are shown and described below with respect to Figures 31-38. These details include advantages and components of the technology, needs and advantages, treatment of the technology, tissue types and preparation, processes, variable tissue particle size, tissue distribution options, clinical indications and development status.

[0125] The present invention is intended to fill an important unmet need: full-thickness skin grafts are the gold standard for chronic wounds and burns, but are rarely used because dermatomes create non-healing donor sites and the procedure must usually be performed in an operating room.

[0126] The present invention allows for the rapid creation of full thickness skin grafts without the traditional healing of a donor site.

[0127] The present invention can also be customized to fit the anatomy of the wound and can be performed as an office procedure. The resulting process of the present invention and the grafts produced thereby are fast, minimally invasive, sterile, provide excellent survival rates, and are a cost-effective solution for wound healing. The system, device, and process of the present invention can be performed at the bedside, including the preparation of morselized TP and the formation of a fluid with a pH to help maintain tissue, and the distribution of TP to the area to be treated, which can be a wound, a cosmetic or plastic surgery area, a visceral area, etc.

[0128] As shown in Figure 31, the use of the apparatus of the present invention, including the processing device 950, applicator 952 and reusable instrument 954, allows for retention of original tissue structure, high tissue / cell viability (90-95%), and the ability to vary tissue particle size. Furthermore, versatile dispensing methods such as spread pastes, sprays, and injectables can be used. All of these are amenable to office procedures and can be completed within about 20 minutes, preferably within about 10 minutes. Furthermore, the present invention allows for the processing of multiple tissue types such as skin, cartilage and organs.

[0129] With reference to FIG. 32, the complete total procedure is completed within 30 minutes. Preparation 955 is improved as the procedure results in rapid healing, low pain levels, rapid collection and processing, and a suture-closed donor site. Processing 956 to form the morselized TP is performed in a closed, sterile system within about 10 minutes. The process is automated, can accommodate a variety of particle sizes, and provides high cell viability (90% or higher, such as 99%). Application 957 can be performed by selectable tips on irregular surfaces and with various wound sizes. Application can also be injectable. Morselized TP of the present invention are desirably prepared at a suitable pH to maintain viability after they have been morselized to their intended size. Fluids containing morselized, highly viable TP can be dispensed onto or into the area to be treated using a conventional syringe. The fluid containing the suspended morselized TP may be applied to wounds or other areas of the body requiring treatment, such as joints of the body, plastic surgery or cosmetic applications, or other areas of use to enhance tissue health and / or the overall appearance and health of the patient.

[0130] Turning now to FIG. 33, as shown therein, the preparation process using both full thickness skin grafts (FTSG) and cartilage grafts (CG).

[0131] 34 shows a basic three step process for morselized abdominoplasty tissue in solution dispensed from a 1 mm syringe, including introduction 958, morselization (cutting the donor site tissue into particles) 959, and dispensing 961.

[0132] FIG. 35 shows variable tissue particle size of full thickness skin graft particles (FTSG) (also called strips) containing cellular and extracellular components using the devices and systems discussed herein according to the process of the present invention.

[0133] FIG. 36 shows a variety of dispensing tip options and devices including spread 980 using a fan tip wiper 981, paste 982 using a cannula 983, spray 984 using a nozzle 985, and injectable 986 using a needle 987, all coming from a suitable applicator device 952.

[0134] FIG. 37 shows non-limiting examples of clinical applications including wound healing 990, cutaneous anesthetic injectable 991, and cartilage repair 992 using an injection device with appropriate tip selection.

[0135] Figure 38 shows morselized tissue of bovine knee articular cartilage, as well as morselized tissue from an abdominal formation formed using the process of the present invention. These morselized cartilage and skin microparticles can be distributed to patients using any of the dispensing devices described herein. The results have repeatedly demonstrated that there is 87-98% cell viability using standard trypan and MTT testing protocols.

[0136] The above description and figures are intended to be illustrative only and are not intended to limit the invention in any manner, except as set forth in the following claims. It is particularly noted that those skilled in the art can readily combine various technical aspects of the elements of the various exemplary embodiments described above in many other ways, all of which are considered to be within the scope of the present invention.

Claims

1. 1. A system for treating skin or cartilage tissue of a patient, comprising: a sterile container for forming therein biological tissue strips in liquid suspension; a morsel device supported within the vessel; an opening in the container in fluid communication with a removable dispensing device; a separator for separating the formed particles from the liquid; a removable dispensing device for receiving the filtered debris; Equipped with The formed strips move through the opening of the container to the dispenser.

2. The system of claim 1 further comprising a liquid drain outlet.

3. The system of claim 1 , wherein the opening in the container is positioned below a location where the strips are formed.

4. The system of claim 1 further comprising a removable or adjacent cover for the container.

5. 10. The system of claim 1, wherein the vessel comprises a separation chamber having an outlet and an inlet for removing the debris and for recirculating the debris back to the vessel.

6. The system of claim 5 , wherein the separation chamber comprises a filtration channel.

7. The system of claim 5 , wherein the separation chamber comprises a filter.

8. The system of claim 5 , wherein the separation chamber comprises an opening for receiving the removable dispensing device.

9. The system of claim 1 , wherein the distributor comprises a filter.

10. The system of claim 1 , further comprising a recirculation conduit in fluid communication with the vessel for recirculating the pieces back to the vessel so as to form smaller pieces.

11. The system of claim 1 further comprising a fluid powered pump for assisting debris circulation.

12. The system of claim 1 , wherein the separator comprises a filter in fluid communication with the vessel for separating suspended debris from the fluid.

13. The system of claim 1 , wherein the separator comprises a centrifuge device in fluid communication with the vessel to separate suspended debris from the fluid.

14. The system of claim 4 , wherein the cover includes a mounting rod having a head biased into a cavity by a spring.

15. The system of claim 1 further comprising a rotating drive shaft.

16. The system of claim 15 , wherein the morsel device is operably connected to the drive shaft.

17. The system of claim 1 further comprising an agitator operably connected to the drive shaft.

18. The system of claim 7 , wherein the filter comprises a cylindrical filter.

19. The system of claim 18 , wherein the cylindrical filter is located within the separation chamber.

20. 20. The system of claim 19, further comprising a piston plunger positioned within the cylindrical filter to facilitate transfer of the debris from the cylindrical filter to the dispensing device.

21. The system of claim 1 , further comprising a channel in fluid communication with the dispensing device and the container, the channel comprising a valve.

22. The system of claim 12 , wherein the strips are directed into a syringe for dispensing.

23. 1. A process for wound healing treatment using autologous micrograft tissue, comprising: removing a biopsy of autologous organ tissue; placing said biopsy material and a sterile fluid in a sterile container; stripping the biopsy material in the container; Separating the debris from the fluid; and transferring the strips to a dispenser; and distributing said strips onto a surface of said wound.

24. 1. A method of treating a patient, comprising: Extracting organ tissue from a donor site of the patient to be treated or from another donor patient; Forming a mass of organ tissue in a fluid using a system, the system comprising: A sterile container; an opening in the container that allows fluid communication with a removable dispensing device; a removable dispensing device for receiving the strips; the formed strip travels through the opening of the container and into the dispensing device; and applying said strip to the area of ​​the patient's body to be treated using said dispensing device.

25. 25. The method of claim 24, wherein the organ tissue is selected from the group consisting of a full thickness skin graft, a split thickness skin graft, or a cartilage graft.

26. 25. The method of claim 24, further comprising a filter for separating the debris from the fluid.

27. 28. The method of claim 27, wherein the fluid is filtered prior to application to the patient.

28. 25. The method of claim 24, wherein the majority of the organ tissue remains viable.

29. 25. The method of claim 24, wherein the donor site is then closed with sutures, staples, adhesives or a combination thereof during healing.

30. 25. The method of claim 24, wherein the formation of the particles occurs in the device in about 1 minute to about 10 minutes.

31. 25. The method of claim 24, wherein the donor site is from the patient's abdomen.

32. 25. The method of claim 24, wherein the dispensing device is a syringe.

33. 25. The method of claim 24, wherein the fluid comprises saline.

34. 25. The method of claim 24, wherein the fluid comprises a component selected from the group consisting of growth factors, drugs, fibrin glue, autologous platelet-rich plasma, and combinations thereof.

35. 25. The method of claim 24, wherein the part of the patient's body being treated is a wound.

36. 25. The method of claim 24, wherein the part of the patient's body being treated is an organ.

37. 25. The method of claim 24, wherein the part of the patient's body to be treated is cosmetic.

38. 1. A method of treating a patient, comprising: extracting a full thickness skin graft from the patient; forming strips of full thickness skin grafts by repeatedly atraumatically slicing the extracted full thickness skin graft in saline using a system comprising: A sterile container; an atraumatic cutting device supported within the container, the cutting device forming the full thickness skin graft strips while preserving the strips viable; an opening in the container in fluid communication with a removable dispensing device; a removable dispensing device for receiving said strips; a filtration device for separating the saline solution from the strips; the strip thus formed passes through an opening in the container and into the dispensing device; and applying said strip to the portion of said patient's body to be treated using said dispensing device.

39. 1. An apparatus for treating organ tissue to maintain tissue viability, comprising: a) a sterile container for containing a fluid and for receiving said organ tissue; b) at least two cutting devices supported in compressive engagement with one another within said sterile container for cutting organ tissue therebetween, at least one of said cutting devices including an open space to allow passage of tissue therethrough, said cutting devices configured to atraumatically cut said tissue with a slicing action; c) an agitation device supported within the sterile container and causing a repeated continuous circulatory flow of the fluid and the organ tissue through the cutting device within the sterile container, the agitation device repeatedly recirculating the fluid and the organ tissue through the cutting device to repeatedly, atraumatically cut the organ tissue while maintaining viability of the tissue; d) the agitator comprises an impeller configured to create a reciprocating flow through the cutting device.

40. 1. An apparatus for processing organ tissue, comprising: a) a sterile container for containing a fluid and for receiving said organ tissue; b) at least two cutting devices supported in compressive physical contact with one another along a common shearing plane within said sterile container, at least one of said cutting devices including an open space to permit passage of tissue therethrough, said cutting devices configured to aerobically cut said tissue; c) an agitation device supported within the sterile container and causing a repeated continuous circulatory flow of the fluid and the organ tissue through the cutting device within the sterile container, the agitation device repeatedly recirculating the fluid and the organ tissue through the cutting device to repeatedly, atraumatically cut the organ tissue while maintaining viability of the tissue; d) the agitator includes an impeller configured to create a reciprocating flow through the cutting device.

41. 1. A method for processing organ tissue into particulate form, comprising the steps of: providing at least two devices supported within a sterile container in compressive engagement with one another; placing a liquid and organ tissue in said container; moving at least one cutting device relative to another cutting device to cut the organ tissue through an opening formed in the at least one cutting device to combine and atraumatically cut the tissue in a slicing motion; and providing an impeller that continuously circulates the fluid and the organ tissue through the cutting device and repeatedly cuts the organ tissue into progressively smaller particles, the impeller being shaped to create the continuous circulation through the device for repeated cutting of the organ tissue.

42. A method for processing organ tissue into particulate form, comprising the steps of: providing at least two cutting devices in compressive contact along a common shear plane supported within a sterile container; placing a fluid and an organ tissue in said container; moving a cutting device relative to another cutting device to atraumatically cut the organ tissue through a breach of the stationary cutting device in a slicing motion; providing an impeller that continuously recirculates the fluid and the organ tissue through the cutting device and repeatedly, atraumatically, cuts the organ tissue into progressively smaller particles, the impeller being shaped to cause the continuous recirculation through the cutting device.

43. Minced tissue particles having a mean diameter of about 0.20 mm to 1.50 mm and having a viability of at least 85%.

44. 44. The comminuted tissue particle of claim 43, wherein said comminuted tissue particle is a comminuted cartilage tissue particle.

45. 45. The morselized cartilage tissue particle of claim 44, having an average size measured across its greatest dimension selected from the group consisting of about 0.35 mm to 1.25 mm, about 0.5 mm to about 1.00 mm, about 0.5 mm to about 0.75 mm, about 0.25 mm to about 0.75 mm, and about 0.50 mm.

46. The comminuted cartilage tissue particle of claim 44, wherein the viability is selected from the group consisting of at least 90%, at least 92%, at least 94%, at least 96%, at least 97%, at least 98%, at least 99%, and 87-98%.

47. 45. The comminuted cartilage tissue particle of claim 44, having an average size measured across its largest dimension of about 0.25mm to 0.75mm and a viability of at least 90%.

48. 45. The comminuted cartilage tissue particle of claim 44, having an average size of about 0.50 mm as measured in its largest dimension.

49. 45. A composition comprising the comminuted cartilage tissue particles of claim 44, said composition being in a form selected from the group consisting of a liquid, a suspension, a dispersion, a cream, a fluid, an emulsion, a paste, a spray, and an injectable.

50. 50. The composition of claim 49, further comprising at least one selected from the group consisting of liquid media, fibrin glue, autologous platelet rich plasma, growth factors, binders, saline, buffers, and cell growth / storage solutions.

51. 51. The composition of claim 50, wherein the liquid medium is a hydrophilic medium, a lipophilic medium, or an emulsion of hydrophilic and hydrophilic media.

52. 50. The composition of claim 49, wherein the composition is in the form of a suspension, and further wherein the suspension is heterogeneous.

53. 50. The composition of claim 49, wherein the composition is in the form of a suspension, and further wherein the suspension is homogenous.

54. 50. A method of repairing or treating cartilage in a patient in need of such treatment, comprising administering to said patient a composition according to claim 49.

55. 55. The method of claim 54, wherein the composition is administered to a joint of the patient.

56. 55. The method of claim 54, wherein the composition is administered to the patient via a syringe or spatula.

57. Minced tissue particles having an average size of about 0.25 mm to 0.75 mm as measured in the largest dimension and having a viability of at least 85%.

58. 58. The comminuted tissue particle of claim 57, wherein said comminuted tissue particle is a comminuted cartilage tissue particle.

59. 59. The comminuted cartilage tissue particle of claim 58, wherein said viability is at least 92%.

60. 59. The comminuted cartilage tissue particle of claim 58, wherein said viability is at least 96%.

61. The comminuted cartilage tissue particle of claim 58, wherein the viability is 87-98%.

62. 59. The comminuted cartilage tissue particle of claim 58, having an average size measured across its greatest dimension of about 0.50 mm and having a viability of at least 90%.

63. 60. A composition comprising the comminuted cartilage tissue particles of claim 58, said composition being in a form selected from the group consisting of a liquid, a suspension, a dispersion, a cream, a fluid, an emulsion, a paste, a spray, and an injectable.

64. 64. The composition of claim 63, wherein the comminuted cartilage tissue particles have an average size measured across their greatest dimension of about 0.50 mm.

65. 64. The composition of claim 63, further comprising at least one selected from the group consisting of liquid media, fibrin glue, autologous platelet rich plasma, growth factors, binders, saline, buffers, and cell growth / storage solutions.

66. 64. A method of repairing or treating cartilage in a patient in need of treatment, comprising administering to said patient a composition according to claim 63.

67. 67. The method of claim 66, wherein the comminuted cartilage tissue particles have an average size measured across their greatest dimension of about 0.50 mm.

68. 67. The method of claim 66, wherein the composition is administered to a joint of the patient.

69. 68. The method of claim 67, wherein the composition is administered to a joint of the patient.

70. 67. The method of claim 66, wherein the comminuted cartilage tissue particles are comminuted articular cartilage tissue particles.

71. 45. The comminuted cartilage tissue particles of claim 44, wherein the source of cartilage tissue is non-articular cartilage, articular cartilage, or a combination thereof.

72. A cartilage graft comprising the morselized cartilage tissue particles of claim 44.

73. 1. A surgical procedure comprising: Removing at least one tissue section from a patient; processing the harvested tissue for less than one hour to prepare comminuted tissue particles, the comminuted tissue particles having an average size measured across their largest dimension of about 0.25 mm to 0.75 mm and a viability of at least 85%; and implanting said comminuted tissue particles into said patient's joint.

74. i) said at least one tissue portion is at least one cartilage tissue portion; ii) the harvested tissue is harvested cartilage; 74. The surgical procedure of claim 73, wherein iii) the comminuted tissue particles are comminuted cartilage tissue particles.

75. 75. The surgical procedure of claim 74, wherein the harvested cartilage is harvested from non-articular or articular cartilage of the patient.

Citation Information

Patent Citations

  • Method and System for Harvesting Biological Tissue

    US20160310157A1

  • Two-dimensional needle array device and method of use

    US20160310159A1